Special Contribution 2014 Update of the Drug Resistance Mutations in HIV-1
By A. Wensing, V. Calvez, H. Günthard, V. Johnson, R. Paredes, D. Pillay, R. Shafer, D. Richman. 2014
160 citations recorded by the source corpus.
This July 2014 edition of the IAS-USA drug resistance mutations list updates the figures last published in March 2013. The following mutations have been added to existing classes or drugs: K65E/N has been added to the bars for the nucleoside and nucleotide analogue reverse transcriptase inhibitors (nRTIs) abacavir, didanosine, emtricitabine, lamivudine, stavudine, and tenofovir; L100I has been added to the bar for the nonnucleoside analogue reverse transcriptase inhibitor (NNRTI) rilpivirine; and F121Y has been added to the bars for the integrase strand transfer inhibitors (InSTIs) dolutegravir, elvitegravir, and raltegravir. With regard to protease inhibitors (PIs), it cannot be excluded that drug resistance may be selected for outside the protease encoding region.
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Sonali Parbhoo
- Finale Doshi-Velez
- Jasmina Bogojeska
- Volker Roth
- Maurizio Zazzi
- Chao Yu
- Adrian Weller
- Jiming Liu
Citations in the corpus
- Combining Kernel and Model Based Learning for HIV Therapy Selection (2017, background): “Resistance mutations are the Single Nucleotide Polymorphisms (SNPs) in the HIV viral genome identified by the International AIDS Society as being associated with drug resistance [10].”